A non-randomized, open-label, multi-dose Phase 1 trial with trastuzumab -deruxtecan (DS-8201a), a HER2-targeting ADC, in HER2-positive GC patients showed a manageable safety profile and showed preliminary activity (153). Here, ERBB2 is linked to gastric cancer.